000 02560nam  2200385zi 4500
0019.914234
003CaOODSP
00520230217083031
006m     o  d f      
007cr mn|||||||||
008220808t20232023onc     ob   f000 0 eng d
020 |a9780660449388
040 |aCaOODSP|beng|erda|cCaOODSP
043 |an-cn---
0861 |aHP40-321/2022E-PDF
24500|aNACI literature review on the effects of palivizumab prophylaxis on reducing the complications associated with respiratory syncytial virus in infants.
24617|aEffects of palivizumab prophylaxis on reducing complications associated with respiratory syncytial virus in infants
264 1|aOttawa, Ontario : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |c2023.
264 4|c©2023
300 |a1 online resource (133 pages)
336 |atext|btxt|2rdacontent
337 |acomputer|bc|2rdamedia
338 |aonline resource|bcr|2rdacarrier
500 |aCover title.
500 |a"Publication date: February 2023."
500 |aAt head of title: An Advisory Committee Review National Advisory Committee on Immunization (NACI).
500 |aIssued also in French under title: Revue de la littérature du CCNI sur les effets de la prophylaxie par palivizumab sur la réduction des complications associées au virus respiratoire syncytial chez les nourrissons.
504 |aIncludes bibliographical references (pages 46-50).
520 |a"The literature review examined the evidence on the effectiveness of palivizumab (PVZ) prophylaxis compared to the administration of placebo or to no prophylaxis in reducing the complications associated with RSV infection in children. The outcomes of interest included hospitalization, length of hospital stay, stay in intensive care, length of stay (LOS) in intensive care, use of oxygen therapy, length of oxygen therapy use, use of mechanical ventilation (MV), length of MV use, long-term sequelae (e.g., wheezing, asthma), and mortality"--Executive summary, page 6.
650 0|aPalivizumab|zCanada.
650 0|aRespiratory syncytial virus|zCanada.
650 0|aInfants|xDiseases|zCanada.
7102 |aPublic Health Agency of Canada, |eissuing body.
77508|tRevue de la littérature du CCNI sur les effets de la prophylaxie par palivizumab sur la réduction des complications associées au virus respiratoire syncytial chez les nourrissons.|w(CaOODSP)9.914235
85640|qPDF|s1.54 MB|uhttps://publications.gc.ca/collections/collection_2023/aspc-phac/HP40-321-2022-eng.pdf